drugset / Trial / NCT00651144

Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)

NCT00651144

Phase 1 Completed 40 enrolled Organon and Co Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to obtain data of the coadministration of ezetimibe and rosuvastatin to support the concomitant use of these two drugs in patients requiring additional cholesterol-lowering management. Treatment is administered for 14 days.

Timeline

Start
2003-03
Primary completion
2003-05
Completion
2003-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ezetimibe Unknown 10 mg Oral
Subject Rosuvastatin Small molecule 10 mg Oral